

Ref no: 287110121  
From: Public  
Date: 11/01/21  
Subject: Treatment of severe asthma

## REQUEST & RESPONSE

I am researching the use of biologic products. Could you please provide answers to the following three questions:

Q1. How many patients have been treated (for any disease) in the last three months with:

- Benralizumab
- Omalizumab
- Reslizumab
- Mepolizumab

**There were 2,652 admitted spells where Asthma was clinically coded.**

Q2. How many patients have been treated in the last three months, for asthma ONLY, with:

- Dupilumab
- Upadacitinib

**Under section 12 of the Freedom of Information Act St Helens & Knowsley Teaching Hospitals Trust does not have to comply with a request if we estimate that the cost of complying with your request would exceed the appropriate limit of £450. The appropriate limit has been specified in regulations. This represents the estimated cost of one person spending 2½ working days in answering the remainder of your questions. Under section 12 of the Freedom of Information Act the Department is not obliged to comply with your request and we will not be processing your request further.**

Q3. How many patients have been treated (with any medication) for severe asthma in the last three months? Of these patients, how many were children?

**No patients in the 3 month time frame (November 2020 to January 2021) were clinically coded with severe asthma.**